Disclaimer: This is an international website for VOTRIENT® (pazopanib) and is intended for health care professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
PIVOTAL TRIAL: A phase 3, randomized (2:1), double-blind, placebo-controlled, multicenter study comparing VOTRIENT with placebo
Eligibility criteria: patients aged ≥18 years with advanced and/or metastatic RCC with progression on 1 prior cytokine-based systemic therapy, clear cell histology, measurable disease, ECOG performance status ≤1, and adequate organ function.
COMPARZ: A phase 3, head-to-head, randomized (1:1), open-label, noninferiority study comparing VOTRIENT with sunitinib
Eligibility criteria: patients aged ≥18 years with advanced RCC, clear cell histology, no prior systemic therapy, measurable disease KPS ≥70%, and adequate organ function.